RBC8

RBC8 is a selective and allosteric RALA and RALB inhibitor. RBC8 stabilizes the inactive GDP-bound state of Ral, preventing its activation. RBC8 promotes the phosphorylation of proteins related to the MAPK/JNK pathway. RBC8 has the activity of inhibiting tumor cell proliferation, migration and invasion. RBC8 is used in the study of various cancers such as lung cancer, gastric cancer, and multiple myeloma^[1][2][3]. In Vitro: RBC8 (10-20 μM; 3-72 h) can reduce the survival rate of myeloma cells AMO-1 and INA-6 and the level of RAL-GTP in sensitive INA-6 cells^[1]. RBC8 (20 μM; 3 days of treatment) inhibits the colony formation of lung cancer cells H2122 and H358 in soft agar with IC₅₀ of 3.5 μM and 3.4 μM, respectively^[2]. RBC8 (20-40 μM) significantly inhibits the growth, migration and invasion of gastric cancer cell lines SGC-7901 and MGC-803^[3]. In Vivo: RBC8 (50 mg/kg; i.p.; daily (except weekends); 21 days) inhibits tumor growth in nude mice inoculated with H2122 and H358 human lung cancer cells^[2].